PRESTO-ENGINEERING
16.1.2023 09:01:40 CET | Business Wire | Press release
Presto Engineering, the recognized microelectronics expert from ASIC design to semiconductor production services, announces a strengthening of its leadership to support its aggressive strategic plan of future growth. Cédric Mayor, VP Global Strategy & Corporate Development, is appointed Chief Executive Officer (CEO) of the company. Previous CEO, and company founder, Michel Villemain, is appointed Executive Chairman, primarily focusing on strategic and corporate development. The change is effective January 11, 2023, and is the result of a year-long transition process initiated by the company’s leadership.
“As a member of the core management team of Presto, Cédric has played a key role in the development of the company over the years, and I am glad that he is stepping up to CEO,” said Thomas Fort, Chairman of the company’s Supervisory Board. “I would also like to thank Michel Villemain for his vision and strong leadership over the years, and I am delighted that Michel is staying on as Executive Chairman. I am looking forward to working with both Cédric and Michel in their new roles.”
“Presto Engineering has come a long way since 2006, when we started it with Frank Sauk in California,” said Michel Villemain. “In the past 16 years, we have established a market leader and created the foundation for further expansion. I wish Cédric all the best in driving the company forward, after all we have done together for Presto since 2009. I want to thank our team—and all who have contributed to Presto’s achievements over the years—for their dedication and efforts and our shareholders for their confidence and support. I look forward to participating in our continued success in this more strategic role.”
“I feel honored to be appointed as the next CEO of Presto Engineering, and together with our extremely talented colleagues, will continue to help our customers create their products through semiconductor innovations and passion,” said Cédric Mayor, incoming CEO of Presto Engineering. “I wish to thank Michel Villemain for this amazing 13-year journey we shared together while continuing working with him in his new role, as well as to the Supervisory Board for their confidence. I look forward to shaping the next chapter of Presto Engineering, while empowering our team to deliver outstanding service and support that exceeds our customers’ expectations.”
Cédric Mayor has more than 23 years of experience in the semiconductor business, which includes 13 years at Presto Engineering across various executive management positions. Cédric has held several technical and executive management roles at NXP Semiconductors, from process release to front-end and back-end of line migration, as part of the asset light company vision. Cédric started his career with SOISIC (a start-up acquired by Arm) as lead architect of silicon embedded memory and compilers. Cédric graduated from Ecole Centrale Marseille in France; he holds an MS in Physics & Electrical Engineering, with several patents and papers in the field.
About Presto Engineering
Presto Engineering provides ASIC design and outsourced operations for semiconductor and IoT device companies, helping its customers minimize overhead, reduce risk, and accelerate time-to-market. The company is a recognized expert in the development of industrial solutions for RF, analog, mixed-signal, and secured applications―from design, tape-out, to delivery of finished goods. Presto’s proprietary, highly secure manufacturing and provisioning solution, coupled with extensive back-end expertise, gives its customers a competitive advantage. The company offers a global, flexible, dedicated framework, with headquarters in Meyreuil, France, and operations across Europe, North America, and Asia. For more information, visit: www.presto-eng.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230116005105/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom